“Demographics, Prior Therapies, and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-Rwlc Survivorship and Epidemiology (C.A.S.E.) Study in Patients With Advanced Cutaneous Squamous Cell Carcinoma”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s125, https://doi.org/10.25251/skin.4.supp.125.